Truist analyst David MacDonald raised the firm’s price target on Humana to $550 from $530 and keeps a Hold rating on the shares. The company’s Q2 results were “solid” with better membership data, the analyst tells investors in a research note. The firm adds that Humana’s core trends remain solid, Medicare Advantage membership expectations continue to rise, and FY24 positioning is attractive further supported by the ongoing integration and expansion of CenterWell.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on HUM:
- Humana sees FY24 adjusted EPS up 11%-15%, consensus $32.09
- Early notable gainers among liquid option names on August 2nd
- Unusually active option classes on open August 2nd
- Humana says ‘committed’ to FY24 adjusted EPS target of $37
- Humana backs FY23 adjusted EPS view to ‘at least’ $28.25, consensus $28.29
